Reuters logo
BRIEF-AbbVie announces approval of Maviret for chronic hepatitis C treatment in Japan
September 27, 2017 / 5:08 AM / 3 months ago

BRIEF-AbbVie announces approval of Maviret for chronic hepatitis C treatment in Japan

Sept 27 (Reuters) - Abbvie Inc

* AbbVie announces approval of Maviret (glecaprevir/pibrentasvir) for the treatment of chronic hepatitis C in all major genotypes (GT1-6) in Japan

* Approval is supported by a 99 percent virologic cure rate in patients Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below